johnson

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

1 week ago

CORRECTION — Innventure announces strategic investment in Accelsius by Johnson Controls

This press release was corrected to specify that Innventure’s private placement was unrelated to the strategic investment in Accelsius by…

3 weeks ago

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a…

2 months ago

Nilesh Shah joins Illumina as Head of Region, AMEA

SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced…

2 months ago

Johnson & Johnson Launches VARIPULSE Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment

The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system,…

4 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

4 months ago

Acceleware Announces Board Appointments

CALGARY, Alberta, June 03, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of…

5 months ago